Biomedical HIV Prevention Research in 2022 and Beyond

This report provides a concise update on the full landscape of biomedical interventions: including PrEP products in the market and next-gen products in the pipeline—multipurpose products (MPTs), vaccines and broadly neutralizing antibodies.

Correlations between Oral Pre-Exposure Prophylaxis (PrEP) Initiations and Policies that Enable the Use of PrEP to Address HIV Globally

This article from PLoS Global Public Health presents the results of an analysis examining whether policies enabling broad PrEP eligibility, HIV self-testing, and lowered age of consent to HIV testing and treatment services are correlated with PrEP uptake.

Celebrating the Role of Communities: A focus on choice in HIV prevention

Presentation given by Rosemary Mburu, Executive Director of WACI Health, on World AIDS Day 2022 describing her organization and providing a short overview of the field.

New Products Are Needed But a New Paradigm is Essential

With all the talk about new HIV prevention products such as the dapivirine vaginal ring or injectable cabotegravir for PrEP (CAB for PrEP), what’s little understood is how to match proven products with the programs, policies and political will needed to get them to the people who need them. This episode explores the shifting landscape in HIV prevention and how this moment gives the world a chance to finally reimagine how to DELIVER prevention.

We go from big picture to grass roots, and dig into what it’s going to take to reach global targets. There’s a new road map out from the Global HIV Prevention Coalition with a big vision and a new target of less than 370,000 new infections by 2025. And PEPFAR’s new Strategic Direction talks about a target for ending the epidemic as a public health threat by 2030, but how are we going to get there?

This episode brings three perspectives together:

PEPFAR Ambassador Dr. John Nkengasong describes a model to scale up prevention in 5 countries and show impact in 1-2 years.

Executive Director of HEPS-Uganda, and former AVAC Advocacy Fellow, Kenneth Mwehonge talks about the commitments needed from a range of stakeholders to bring the Coalition’s new roadmap to life, and hit 2030 targets.

Lilian Benjamin Mwakyosi, the Executive Director of DARE and former AVAC Advocacy Fellow, talks about the day-to-day obstacles faced by young women who need prevention, what’s working now and what needs to change in HIV prevention programs.

Highlights

  • Listen to the ambassador’s appeal for an aggressive strategy to scale up combination prevention, including injectable cabotegravir for PrEP.

Resources

Combination Prevention: Integrating strategies to end the epidemic

One-pager describing what “combination prevention” means.

PrEPWatch

PrEPWatch is designed to be a clearinghouse for information on PrEP research (ongoing and completed; clinical trials and demonstration projects), data, additional research, cost, access and advocacy efforts across the globe.

Px Wire July-September 2022, Vol. 12, No. 2

PrEP Tracker data, preparing for new products, the HIV prevention pipeline and our prevention playlist. All that and more in the latest issue of Px Wire.

PEP Needs Some Pep! Addressing PEP Neglect in HIV Prevention Research, Programming and Uptake

Thursday, November 3, 2022

During this webinar, experts and advocates addressed why PEP has been long neglected in HIV prevention research, programming, and uptake.

Featuring Dr. James Ayieko, Dr. Julie Fox, Dr. Ken Mayer, Dr, Catherine Koss, Njambi Njuguna and Ace Robinson

Recording / Slides / Resources

Cost of Goods Sold (COGS) Analyses

FAQ Debrief

This FAQ explains the use of Cost of Good Sold Analyses (COGS) and how they inform planning for product introduction.

Access to the Dapivirine Vaginal Ring: A timeline on progress